Alumis (NASDAQ:ALMS) Coverage Initiated at Morgan Stanley

Morgan Stanley began coverage on shares of Alumis (NASDAQ:ALMS) in a research report sent to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $36.00 price objective on the stock.

Alumis Stock Up 0.3 %

Shares of Alumis stock opened at $12.85 on Tuesday. Alumis has a 52-week low of $10.45 and a 52-week high of $13.53.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.